Literature DB >> 12742990

Intramural delivery of recombinant apolipoprotein A-IMilano/phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteries.

Sanjay Kaul1, Vladimir Rukshin, Raul Santos, Babak Azarbal, Charles L Bisgaier, Jan Johansson, Vivian T Tsang, Kuang-Yuh Chyu, Bojan Cercek, James Mirocha, Prediman K Shah.   

Abstract

BACKGROUND: We have previously demonstrated vasculoprotective effects after repeated intravenous administration of recombinant apolipoprotein A-IMilano (apoA-Im)/phospholipid complex. In this study, we sought to determine the effects of local recombinant apoA-Im/1-palmitoyl,2-oleoyl phosphatidylcholine complex (ETC-216) delivered intramurally via the Infiltrator catheter on luminal narrowing in a porcine coronary artery stent overstretch injury model. METHODS AND
RESULTS: In twelve domestic swine ( approximately 25 kg), two arteries each were infiltrated with 0.4 mL ETC-216 (14 mg/mL) or vehicle control immediately before deployment of GFX stents (stent:artery ratio=1.3:1). Animals were euthanized at day 28, and evaluation by QCA revealed a significant improvement in mean lumen loss index with ETC-216 treatment (21+/-22% versus 43+/-13% lumen loss; P=0.01). Histomorphometric analysis showed that ETC-216 treatment significantly reduced the intimal area (6.7+/-1.5 versus 5.2+/-1.4 mm2, -22%; P=0.02) and the stenosis index (0.76+/-0.15 versus 0.59+/-0.15; P=0.01), and increased the lumen area (2.1+/-1.4 versus 3.7+/-1.8 mm2, +76%; P=0.02). Regression analysis showed significant differences in lumen area (P=0.004), neointimal area (P=0.003), stenosis index (P=0.001), and neointimal thickness (P=0.003) adjusted for injury score in favor of ETC-216.
CONCLUSIONS: A single intramural administration of ETC-216 significantly inhibited injury-induced luminal narrowing in the porcine stent overstretch model through reduction of intimal hyperplasia. These data show that local intracoronary delivery of ETC-216 may be useful to prevent restenosis after coronary stenting.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12742990     DOI: 10.1161/01.CIR.0000074042.19447.B1

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  17 in total

1.  Can we stabilize unstable plaque?

Authors:  Rodolfo Paoletti; Andrea Cignarella
Journal:  Curr Atheroscler Rep       Date:  2003-11       Impact factor: 5.113

Review 2.  Raising high-density lipoprotein cholesterol: innovative strategies against an old adversary.

Authors:  Dhruv Kazi; John A Farmer
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

Review 3.  Perspectives and opportunities for nanomedicine in the management of atherosclerosis.

Authors:  Mark E Lobatto; Valentin Fuster; Zahi A Fayad; Willem J M Mulder
Journal:  Nat Rev Drug Discov       Date:  2011-10-21       Impact factor: 84.694

4.  Conformation of dimeric apolipoprotein A-I milano on recombinant lipoprotein particles.

Authors:  Shaila Bhat; Mary G Sorci-Thomas; Laura Calabresi; Michael P Samuel; Michael J Thomas
Journal:  Biochemistry       Date:  2010-06-29       Impact factor: 3.162

Review 5.  Role of HDL in those with diabetes.

Authors:  Carlos G Santos-Gallego; Robert S Rosenson
Journal:  Curr Cardiol Rep       Date:  2014-09       Impact factor: 2.931

6.  Apo A-I (Apolipoprotein A-I) Vascular Gene Therapy Provides Durable Protection Against Atherosclerosis in Hyperlipidemic Rabbits.

Authors:  Bradley K Wacker; Nagadhara Dronadula; Lianxiang Bi; Alexis Stamatikos; David A Dichek
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-11-09       Impact factor: 8.311

7.  Inhibition of collar-induced carotid atherosclerosis by recombinant apoA-I cysteine mutants in apoE-deficient mice.

Authors:  Xinbo Zhang; Xuewei Zhu; Baosheng Chen
Journal:  J Lipid Res       Date:  2010-09-03       Impact factor: 5.922

Review 8.  Progress in HDL-based therapies for atherosclerosis.

Authors:  Kuang-Yuh Chyu; Anish Peter; Prediman K Shah
Journal:  Curr Atheroscler Rep       Date:  2011-10       Impact factor: 5.113

Review 9.  The therapeutic potential of high-density lipoprotein mimetic agents in coronary artery disease.

Authors:  Philippe Meyer; Anil Nigam; Michel Marcil; Jean-Claude Tardif
Journal:  Curr Atheroscler Rep       Date:  2009-09       Impact factor: 5.113

10.  Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo.

Authors:  Frank M Sacks; Lawrence L Rudel; Adam Conner; Hassibullah Akeefe; Gerhard Kostner; Talal Baki; George Rothblat; Margarita de la Llera-Moya; Bela Asztalos; Timothy Perlman; Chunyu Zheng; Petar Alaupovic; Jo-Ann B Maltais; H Bryan Brewer
Journal:  J Lipid Res       Date:  2009-01-14       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.